Are there geographic differences in the outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib (su)?

被引：0
|
作者：
Keizman, Daniel
Ish-Shalom, Maya
Maimon, Natalie
Gottfried, Maya
Pili, Roberto
Hammers, Hans J.
Eisenberger, Mario A.
Sinibaldi, Victoria J.
Boursi, Ben
Weitzen, Rony
Hayat, Henry
Peer, Avivit
Neumann, Avivit
Kovel, Svetlana
Sella, Avishay
Mermershtain, Wilmosh
Rouvinov, Keren
Berger, Raanan
Carducci, Michael Anthony
机构：
[1] Tel Aviv Univ, Genitourinary Oncol Serv, Div Oncol, Meir Med Ctr,Sackler Sch Med, Kefar Sava, Israel
[2] Meir Med Ctr, Lung Canc Unit, Kefar Sava, Israel
[3] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[4] Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[5] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[6] Chaim Sheba Med Ctr, Ramat Gan, Israel
[7] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel
[8] Wolfson Med Ctr, Dept Oncol, Holon, Israel
[9] Rambam Hlth Care Campus, Haifa, Israel
[10] Rambam Med Ctr, Dept Oncol, Haifa, Israel
[11] Asaf Harofe Med Ctr, Dept Oncol, Zerifin, Israel
[12] Assaf Harofeh Med Ctr, IL-70300 Zerifin, Israel
[13] Soroka Med Ctr, Beer Sheva, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15598
引用
收藏
页数：1
相关论文
共 50 条
  • [31] SUNITINIB (SU) RECHALLENGE IN METASTATIC RENAL CELL CARCINOMA (MRCC): A SINGLE INSTITUTION EXPERIENCE
    Febbraro, Antonio
    Giordano, Guido
    [J]. ANTICANCER RESEARCH, 2014, 34 (05) : 2626 - 2627
  • [32] Side effects of sunitinib malate (SM) treatment for patients (pts) with metastatic renal cell carcinoma (mRCC)
    Carteni, G. G.
    Montano, M.
    Perrotta, E.
    Otero, M.
    Guida, T.
    Ragone, G.
    Aurilio, G.
    Maiorino, L.
    Stavolo, C.
    Panza, N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Long-term safety with sunitinib (SU) in metastatic renal cell carcinoma (mRCC)
    Porta, C.
    Gore, M. E.
    Rini, B. I.
    Escudier, B.
    Charles, L. P.
    Chen, L.
    Hariharan, S.
    Motzer, R. J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S658 - S658
  • [34] Sunitinib safety and tolerability in patients with metastatic renal cell carcinoma (MRCC)
    Ferrari, A.
    Sabbatini, R.
    Maur, M.
    Giovannelli, S.
    Jovic, G.
    Conte, P.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : XI83 - XI83
  • [35] Outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with systemic therapy without cytoreductive nephrectomy (CN)
    Richey, S. L.
    Culp, S. H.
    Wood, C. G.
    Corn, P. G.
    Jonasch, E.
    Tannir, N. M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [36] Timing of adverse events (AEs) in sunitinib (SU) treated patients with metastatic renal cell carcinoma (mRCC) and implications for a 2/1 schedule
    Lee, Joseph
    Benedict, Agnes
    Cappelleri, Joseph
    Sandin, Rickard
    Ramaswamy, Krishnan
    [J]. BJU INTERNATIONAL, 2016, 118 : 22 - 22
  • [37] A phase II study of intermittent sunitinib in previously untreated patients (pts) with metastatic renal cell carcinoma (mRCC).
    Wood, Laura S.
    Dreicer, Robert
    Garcia, Jorge A.
    Gilligan, Timothy D.
    Ali, Khaled B.
    Haddad, Housam
    Shah, Shetal N.
    Elson, Paul
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Phase 1/2 study of sunitinib in combination with gefitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    Redman, B. G.
    Hudes, G. R.
    Kondagunta, G. V.
    Patel, P. H.
    Kim, S. T.
    Chen, I.
    Motzer, R. J.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 302 - 302
  • [39] Is There a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?
    Keizman, Daniel
    Rouvinov, Keren
    Sella, Avishay
    Gottfried, Maya
    Maimon, Natalie
    Kim, Jenny J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria
    Peer, Avivit
    Carducci, Michael A.
    Mermershtain, Wilmosh
    Leibowitz-amit, Raya
    Weitzen, Rony
    Berger, Raanan
    [J]. CANCER RESEARCH AND TREATMENT, 2016, 48 (01): : 281 - 287
  • [40] Utility values among patients (pts) with metastatic renal cell carcinoma (mRCC) receiving first-line treatment with pazopanib (PZ) and sunitinib (SU).
    Hagiwara, May
    Park, Jinhee
    Delea, Thomas E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345